Advertisement

European Society of Cardiology Congress: PARADIGM-HF Discussion, 4 New Studies — Physician’s First Watch

Medical News |
September 3, 2014

European Society of Cardiology Congress: PARADIGM-HF Discussion, 4 New Studies

By the Editors

On CardioExchange, the authors of the groundbreaking PARADIGM-HF trial — presented over the weekend at the European Society of Cardiology Congress — answer questions from Harlan Krumholz and readers about how their results could change the management of heart failure.

Meanwhile, NEJM Journal Watch Cardiology shares its coverage of four additional trials presented at the meeting:

  • ATLANTIC: In patients with ST-segment elevation myocardial infarction (STEMI), reperfusion rates did not differ whether the antiplatelet ticagrelor was administered in the ambulance or in the cath lab.

  • SIGNIFY: Ivabradine lowered heart rate but did not improve outcomes among patients with stable coronary artery disease who did not have heart failure. (The drug is available in Europe but not the U.S.)

  • SOLID-TIMI 52: The investigational drug darapladib proved ineffective for secondary prevention after acute coronary events.

  • TASTE: A randomized trial provides strong evidence to skip the aspiration catheter before percutaneous coronary intervention for STEMI.

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement